Publications

Laadem A, Cvitkovic E.

Oxaliplatin: a first DACH-platinum in oncology. Bull Cancer. 2001 Aug; 88 Spec No: S9-13. Review. French.

Bensmaine MA, Marty M, de Gramont A, Brienza S, Levi F, Ducreux M, Francois E, Gamelin E, Bleiberg H, Cvitkovic E.

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. Br J Cancer. 2001 Aug 17; 85(4):509-17.

Monnet I, Soulie P, de Cremoux H, Saltiel-Voisin S, Bekradda M, Saltiel JC, Brain E, Dupont-Andre G, Cvitkovic E.

Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology. 19(2):458-63, 2001.

Sparidans RW, Rosing H, Hillebrand MJ, Lopez-Lazaro L, Jimeno JM, Manzanares I, van Kesteren C, Cvitkovic E , van Oosterom AT, Schellens JH, Beijnen JH.

Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man. Anticancer Drugs. 2001 Sep; 12(8):653-66.

Van Kesteren C, Mathjt RA, Lopez-Lazaro L, Cvitkovic E, Taamma A, Jimeno JM, Guzman C, Schellens JH, Misset JL, Brain E, Hillebrand MJ, Rosing H, Beijnen JH.

A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion. Cancer Chemother Pharmacol. 2001 Dec; 48(6):459-66.

Wasserman E, Sutherland W, Cvitkovic E.

Fizazi K, Caliandro R, Soulie P, Fandi A, Daniel C, Bedin A, Doubre H, Viala J, Rodier J, Trandafir L, Le Chevalier T, Cvitkovic E, Armand J, Ruffie P.

Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur J Cancer. 2000 Aug; 36(12):1514-21.

Fandi A, Bachouchi M, Azli N, Taamma A, Boussen H, Wibault P, Eschwege F, Armand JP, Simon J, Cvitkovic E.

Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol. 2000 Mar;18(6):1324-30.

Kempen I., Pochet L., Doucet C., Lacan F., Bourdel F., Reboud-Ravaux M., Noel A., Foidart J-M., Pirotte B.

Inhibition of cancer cells invasion by coumarin derivatives. Scientific Meeting of the Belgian Association for Cancer Research – Invasion and Metastasis, January 29, 2000, Ghent – Belgium

Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E. Oxaliplatin clinical activity

A review. Crit Rev Oncol Hematol. 2000 Aug;35(2):75-93. Review.

Van Kesteren C, Cvitkovic E, Taamma A, Lopez-Lazaro L, Jimeno JM, Guzman C, Math RA, Schellens JH, Misset JL, Brain E, Hillebrand MJ, Rosing H, Beijnen JH.

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res. 2000 Dec;6(12):4725-32.

Goldwasser F, Gross-Goupil M, Tigaud JM, Di Palma M, Marceau-Suissa J, Wasserman E, Yovine A, Misset JL, Cvitkovic E.

Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients. Ann Oncol. 2000 Nov;11(11):1463-70.